Needham & Company Downgrades Theravance Biopharma (TBPH) to Hold, Following Strategic Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Theravance Biopharma (TBPH) PT Lowered to $7 at Baird
September 16, 2021 8:17 AM EDTBaird analyst Brian Skorney lowered the price target on Theravance Biopharma (NASDAQ: TBPH) to $7.00 (from $10.00) while maintaining a Neutral rating.
... MoreTheravance Biopharma (TBPH) PT Lowered to $8 at Cowen
September 15, 2021 3:55 PM EDTCowen analyst Marc Frahm lowered the price target on Theravance Biopharma (NASDAQ: TBPH) to $8.00 (from $14.00) while maintaining a Market Perform rating.
The analyst commented, "Theravance announced that the Phase 3 SEQUOIA trial of ampreloxetine in nOH did not demonstrate an impact on the... More
